VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
LFMDLifeMD, Inc.
$4.75$230M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist

LFMD logoLifeMD, Inc.(LFMD)Earnings, Financials & Key Ratios

LFMD•NASDAQ
Price updated Jun 19, 2026
SectorHealthcareIndustryPharmaceuticalsSub-IndustryDigital Health and Online Pharmacy
AboutLifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including concierge care, men's sexual health, dermatology, and others in the United States. The company provides ShapiroMD, a telehealth platform brand that offers access to virtual medical treatment, prescription medications, patented-doctor formulated OTC products, and an FDA approved medical device for male and female hair loss, and female specific topical compounded medications for hair loss; RexMD, a men's telehealth brand that offers virtual medical treatment from licensed providers for a variety of men's health needs; LifeMD Primary Care, a personalized subscription-based virtual primary care platform that provides patients with primary care, urgent care, and chronic care needs, as well as .offers a mobile first platform that incorporates virtual consultations and treatment, prescription medications, diagnostics, and imaging; Cleared, a telehealth brand that provides personalized treatments for allergy, asthma, and immunology; and Nava MD, a female-oriented tele-dermatology and skincare brand that offers virtual medical treatment from dermatologists and other providers. It also offers PDFSimpli, an online software-as-a-service platform that allows users to create, edit, convert, sign, and share PDF documents. LifeMD sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.Show more
  • Revenue$194M-8.7%
  • EBITDA-$361K+94.6%
  • Net Income-$7M+62.4%
  • EPS (Diluted)-0.23+56.6%
  • Gross Margin79.75%-10.1%
  • EBITDA Margin-0.19%+94.1%
  • Operating Margin-3.95%+48.0%
  • Net Margin-3.66%+58.8%
  • ROE-74.37%+97.0%

LFMD Key Insights

LifeMD, Inc. (LFMD) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Strong 5Y profit CAGR of 34.4%
  • ✓Momentum leader: RS Rating 82 (top 18%)
  • ✓Strong 5Y sales CAGR of 39.1%
  • ✓Efficient asset utilization: 2.8x turnover

✗Weaknesses

  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when LFMD posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

LFMD Price & Volume

LifeMD, Inc. (LFMD) stock price & volume — 10-year historical chart

Loading chart...

LFMD Growth Metrics

LifeMD, Inc. (LFMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years66.03%
5 Years39.08%
3 Years17.69%
TTM-6.18%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-66.04%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-30.12%

Return on Capital

10 Years-346.01%
5 Years-220.68%
3 Years-96.13%
Last Year-37.37%

LFMD Recent Earnings

LifeMD, Inc. (LFMD) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 6, 2026
Metric
Actual
Est
EPS
$0.20-42.9%
$0.14
Rev
$50M+2.7%
$49M
Q2 2026
Mar 9, 2026
Metric
Actual
Est
EPS
$0.04-300.0%
$0.01
Rev
$47M+2.3%
$46M
Q4 2025
Nov 17, 2025
Metric
Actual
Est
EPS
$0.10-66.7%
$0.06
Rev
$60M+23.9%
$49M
Q3 2025
Aug 5, 2025
Metric
Actual
Est
EPS
$0.05-126.0%
$0.18
Rev
$62M-6.2%
$66M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 6, 2026
$0.20vs $0.14-42.9%
$50Mvs $49M+2.7%
Q2 2026Mar 9, 2026
$0.04vs $0.01-300.0%
$47Mvs $46M+2.3%
Q4 2025Nov 17, 2025
$0.10vs $0.06-66.7%
$60Mvs $49M+23.9%
Q3 2025Aug 5, 2025
$0.05vs $0.18-126.0%
$62Mvs $66M-6.2%
Based on last 12 quarters of dataView full earnings history →

LFMD Peer Comparison

LifeMD, Inc. (LFMD) competitors in Digital Health and Online Pharmacy — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
Institutional Holdings
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
HIMS logoHIMSHims & Hers Health, Inc.Direct Competitor7.79B35.4769.5559%-0.56%-2.48%2.34
NUVB logoNUVBNuvation Bio Inc.Direct Competitor1.93B5.56-9.276.99%-102.06%-44.1%0.03
DOCS logoDOCSDoximity, Inc.Direct Competitor3.83B20.4620.8813.05%30.4%19.36%0.01
OPRX logoOPRXOptimizeRx CorporationDirect Competitor93.45M4.9818.4418.78%6.37%5.47%0.20
TDOC logoTDOCTeladoc Health, Inc.Product Competitor1.46B8.07-7.08-1.54%-6.81%-12.37%0.75
AMWL logoAMWLAmerican Well CorporationProduct Competitor140.85M8.43-1.41-1.98%-48.16%-33.48%0.02
TALK logoTALKTalkspace, Inc.Product Competitor872.74M5.21130.2522%0.49%1.03%
GDRX logoGDRXGoodRx Holdings, Inc.Product Competitor922.03M2.6631.180.57%3.74%4.75%0.10

Compare LFMD vs Peers

LifeMD, Inc. (LFMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs HIMS

Most directly comparable listed peer for LFMD.

Scale Benchmark

vs AMZN

Larger-name benchmark to compare LFMD against a more recognizable public peer.

Peer Set

Compare Top 5

vs HIMS, NUVB, DOCS, OPRX

LFMD Income Statement

LifeMD, Inc. (LFMD) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue
5.05M8.32M12.47M37.29M92.88M119.03M152.55M212.45M194.06M219.42M
Revenue Growth %
-3.51%64.68%49.79%199.1%149.04%28.16%28.15%39.27%-8.66%-6.18%
Cost of Goods Sold
1.48M1.97M2.53M8.86M18M18.67M18.9M24.07M39.29M29.28M
COGS % of Revenue
29.35%23.65%20.25%23.76%19.38%15.68%12.39%11.33%20.25%-
Gross Profit
3.57M▲ 0%
6.36M▲ 78.0%
9.94M▲ 56.5%
28.43M▲ 185.9%
74.88M▲ 163.4%
100.37M▲ 34.0%
133.65M▲ 33.2%
188.39M▲ 41.0%
154.76M▼ 17.8%
190.14M▲ 0%
Gross Margin %
70.65%76.35%79.75%76.24%80.62%84.32%87.61%88.67%79.75%86.65%
Gross Profit Growth %
8.46%77.96%56.46%185.95%163.36%34.03%33.16%40.96%-17.85%-
Operating Expenses
4.64M8.41M12.83M86.25M129.18M143.81M148.14M204.53M162.43M194.93M
OpEx % of Revenue
91.77%101.05%102.92%231.28%139.09%120.82%97.11%96.27%83.7%-
Selling, General & Admin
4.64M8.41M11.31M84.01M122.08M125.33M128.15M175.68M144.01M172.43M
SG&A % of Revenue
91.77%101.05%90.75%225.27%131.44%105.29%84%82.69%74.21%-
Research & Development
0120.54K222.88K446.75K948.16K2.97M6.06M9.51M7.35M7.41M
R&D % of Revenue
-1.45%1.79%1.2%1.02%2.5%3.97%4.48%3.79%-
Other Operating Expenses
0-516.98K1.3M1.79M6.16M15.51M13.93M19.34M11.07M3M
Operating Income
-1.07M▲ 0%
-2.06M▼ 92.6%
-2.89M▼ 40.5%
-57.82M▼ 1900.9%
-54.3M▲ 6.1%
-43.45M▲ 20.0%
-14.49M▲ 66.7%
-16.14M▼ 11.4%
-7.67M▲ 52.5%
-12.9M▲ 0%
Operating Margin %
-21.12%-24.7%-23.18%-155.04%-58.47%-36.5%-9.5%-7.6%-3.95%-5.88%
Operating Income Growth %
9.12%-92.61%-40.54%-1900.94%6.09%19.99%66.65%-11.43%52.49%-
EBITDA
160.82K-1.86M-2.55M-57.48M-53.95M-42.36M-7.89M-6.65M-361.24K-5.14M
EBITDA Margin %
3.18%-22.35%-20.48%-154.14%-58.08%-35.59%-5.17%-3.13%-0.19%-2.34%
EBITDA Growth %
114.22%-1256.79%-37.28%-2150.74%6.16%21.48%81.38%15.67%94.57%-255.29%
D&A (Non-Cash Add-back)
1.23M195.78K335.61K335.61K355.87K1.09M6.6M9.49M7.31M7.76M
EBIT
-1.28M-2.06M-2.89M-57.82M-54.3M-39.69M-14.49M-16.14M-7.67M-5.13M
Net Interest Income
-100.52K-354.39K-761.15K-1.67M-3.02M-1.28M-2.6M-2.18M-1.36M-791.17K
Interest Income
0000000000
Interest Expense
100.52K354.39K761.15K1.67M3.02M1.28M2.6M2.18M1.36M791.17K
Other Income/Expense
-150.91K-354.39K-761.15K-2.58M-7.02M-1.21M-2.92M-2.18M-2.52M-2M
Pretax Income
-1.22M▲ 0%
-1.48M▼ 21.9%
-3.65M▼ 145.9%
-60.4M▼ 1554.5%
-61.32M▼ 1.5%
-44.66M▲ 27.2%
-17.41M▲ 61.0%
-18.33M▼ 5.3%
-10.19M▲ 44.4%
-14.9M▲ 0%
Pretax Margin %
-24.11%-17.84%-29.28%-161.96%-66.02%-37.52%-11.41%-8.63%-5.25%-6.79%
Income Tax
-12.49K-124.7K-122.5K122.5K7.7K360.7K428K402K45.72K959.6K
Effective Tax Rate %
1.02%8.4%3.36%-0.2%-0.01%-0.81%-2.46%-2.19%-0.45%-6.44%
Net Income
-1.21M▲ 0%
-1.24M▼ 2.9%
-3.14M▼ 152.8%
-58.65M▼ 1769.4%
-60.9M▼ 3.8%
-45.54M▲ 25.2%
-20.6M▲ 54.8%
-18.88M▲ 8.3%
-7.11M▲ 62.4%
-17.03M▲ 0%
Net Margin %
-23.86%-14.91%-25.16%-157.26%-65.57%-38.25%-13.5%-8.89%-3.66%-7.76%
Net Income Growth %
-8.89%-2.89%-152.83%-1769.4%-3.84%25.23%54.77%8.32%62.36%-66.04%
Net Income (Continuing)
-1.38M-2.29M-3.53M-60.52M-61.32M-45.02M-17.84M-18.73M-10.23M-15.86M
Discontinued Operations
000000003.13M-409.26K
Minority Interest
-259.08K-77.96K-141.06K-2.18M-1.03M-475.55K2.06M1.44M00
EPS (Diluted)
-0.14▲ 0%
-0.14▲ 0.0%
-0.36▼ 157.1%
-4.24▼ 1077.8%
-2.27▲ 46.5%
-1.57▲ 30.8%
-0.70▲ 55.4%
-0.53▲ 24.3%
-0.23▲ 56.6%
-0.36▲ 0%
EPS Growth %
12.5%0%-157.14%-1077.78%46.46%30.84%55.41%24.29%56.6%-30.12%
EPS (Basic)
-0.14-0.14-0.36-4.24-2.27-1.57-0.70-0.53-0.23-
Diluted Shares Outstanding
8.8M9.05M9.9M14.28M27.01M30.98M33.91M41.2M45.13M47.34M
Basic Shares Outstanding
8.8M8.84M9.9M14.28M27.01M30.98M33.91M41.2M45.13M47.34M
Dividend Payout Ratio
----------

LFMD Balance Sheet

LifeMD, Inc. (LFMD) balance sheet — assets, liabilities & shareholders' equity

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Total Current Assets
1.26M1.61M2.75M12.41M44.92M11.31M42.6M48.73M51.83M51.7M
Cash & Short-Term Investments
141.38K180.09K1.11M9.18M41.33M3.96M33.15M35M36.79M34.48M
Cash Only
141.38K180.09K1.11M9.18M41.33M3.96M33.15M35M36.79M34.48M
Short-Term Investments
0000000000
Accounts Receivable
128.19K99.05K97.45K997.76K980.05K2.83M5.28M8.22M9.31M9.86M
Days Sales Outstanding
9.264.342.859.773.858.6912.6314.1217.514.86
Inventory
707.16K1.02M950.06K1.26M1.62M3.7M2.76M2.8M2.77M3.18M
Days Inventory Outstanding
173.97189.56137.3252.0832.7972.4153.342.4225.7639.37
Other Current Assets
296.48K270.01K442.97K154.88K793.19K687.02K934.51K2.67M2.97M4.19M
Total Non-Current Assets
01.01M699.08K990.26K5M14.35M15.88M23.73M18.58M18.43M
Property, Plant & Equipment
0023.63K274.44K1.99M1.68M1.07M7.88M5.27M5.06M
Fixed Asset Turnover
--527.77x135.89x46.76x70.75x142.41x26.96x36.84x36.92x
Goodwill
0000000000
Intangible Assets
01.01M675.45K715.82K3.02M12.67M14.81M15.85M262.33K230.42K
Long-Term Investments
0000000000
Other Non-Current Assets
0000000013.05M13.14M
Total Assets
1.26M▲ 0%
2.62M▲ 107.0%
3.45M▲ 31.7%
13.4M▲ 288.9%
49.92M▲ 272.5%
25.67M▼ 48.6%
58.48M▲ 127.9%
72.46M▲ 23.9%
70.41M▼ 2.8%
70.12M▲ 0%
Asset Turnover
4.00x3.18x3.62x2.78x1.86x4.64x2.61x2.93x2.76x3.13x
Asset Growth %
60.01%107%31.73%288.92%272.48%-48.59%127.85%23.9%-2.83%-1.36%
Total Current Liabilities
640.97K1.19M3.98M13.93M22.83M31.37M34.78M60.26M41.57M49.59M
Accounts Payable
473.49K869K3M10.41M9.06M10.11M11.08M16.01M14.15M21.65M
Days Payables Outstanding
116.48161.08433.34428.72183.75197.61214.07242.78131.43248.2
Short-Term Debt
167.48K247.42K814.73K779.13K63.4K2.8M327.6K8.44M642.42K670.83K
Deferred Revenue (Current)
-473.49K75.98K0916.88K1.5M5.55M8.83M14.48M10.81M48.97M
Other Current Liabilities
-422.35K-869K109.55K237.04K1.66M576.03K10.93M5.11M15.97M15.24M
Current Ratio
1.97x1.35x0.69x0.89x1.97x0.36x1.22x0.81x1.25x1.04x
Quick Ratio
0.87x0.49x0.45x0.80x1.90x0.24x1.15x0.76x1.18x0.98x
Cash Conversion Cycle
66.7432.82-293.17-366.88-147.11-116.51-148.14-186.24-88.16-193.97
Total Non-Current Liabilities
0604K599.98K292.32K1.28M1.6M18.13M16.25M5.68M5.5M
Long-Term Debt
00000017.93M9.89M05.5M
Capital Lease Obligations
0029.98K192.32K1.18M574.14K73.85K6.27M5.68M17.57M
Deferred Tax Liabilities
04K00000000
Other Non-Current Liabilities
0600K570K100K100K1.02M131.25K100K00
Total Liabilities
640.97K1.8M4.58M14.22M24.1M32.97M52.91M76.51M47.25M55.09M
Total Debt
167.48K247.42K844.71K1.06M1.85M4.13M18.93M25.1M6.32M6.17M
Net Debt
26.1K67.32K-261.91K-8.11M-39.48M168.52K-14.21M-9.9M-30.46M-28.31M
Debt / Equity
0.27x0.30x--0.07x-3.40x-0.27x0.41x
Debt / EBITDA
1.04x---------1.20x
Net Debt / EBITDA
0.16x--------5.51x
Interest Coverage
-12.72x-5.80x-3.80x-34.67x-17.98x-31.10x-5.58x-7.40x-5.64x-6.48x
Total Equity
622.84K▲ 0%
819.74K▲ 31.6%
-1.13M▼ 237.8%
-821.76K▲ 27.2%
25.82M▲ 3241.9%
-7.31M▼ 128.3%
5.57M▲ 176.2%
-4.05M▼ 172.7%
23.16M▲ 672.4%
15.04M▲ 0%
Equity Growth %
272.19%31.61%-237.76%27.23%3241.91%-128.29%176.19%-172.68%672.42%4876.11%
Book Value per Share
0.070.09-0.11-0.060.96-0.240.16-0.100.510.32
Total Shareholders' Equity
881.92K897.7K-988.18K1.35M26.85M-6.83M3.51M-5.49M23.16M15.04M
Common Stock
444.93K457.82K106.81K234.34K307.05K315.53K383.59K422.94K467.6K476.33K
Retained Earnings
-10.9M-12.14M-16.59M-80.15M-141.92M-190.56M-214.27M-236.25M-228.6M-238.25M
Treasury Stock
-163.7K-163.7K-163.7K-163.7K-163.7K-163.7K-163.7K-163.7K-163.7K0
Accumulated OCI
0000000000
Minority Interest
-259.08K-77.96K-141.06K-2.18M-1.03M-475.55K2.06M1.44M00

LFMD Cash Flow Statement

LifeMD, Inc. (LFMD) cash flow — operating, investing & free cash flow history

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Cash from Operations
-817.22K-905.52K251.41K-12.13M-33.09M-22.94M8.82M17.51M8.28M5.66M
Operating CF Margin %
-16.17%-10.88%2.02%-32.53%-35.62%-19.27%5.78%8.24%4.27%-
Operating CF Growth %
-100.34%-10.81%127.76%-4925.47%-172.72%30.68%138.46%98.56%-52.72%-406.75%
Net Income
-1.21M-1.36M-3.53M-60.52M-61.32M-45.02M-20.6M-18.73M15.62M-17.03M
Depreciation & Amortization
91.56K195.78K335.61K397.76K868.76K3.77M6.6M9.49M328.37K-2.76M
Stock-Based Compensation
162.74K273.57K733.22K18.66M12.07M13.73M12.49M12.23M10.5M7.95M
Deferred Taxes
-90.28K4K66K914.86K0354K0000
Other Non-Cash Items
918.01K237.2K578.61K19.63M6.17M5.78M5.42M1.87M-10.31M-4.94M
Working Capital Changes
-693.28K-255.97K2.07M8.8M9.13M-1.55M4.91M12.65M-7.85M4.9M
Change in Receivables
95.09K29.14K1.6K-550.97K17.7K-2.19M-2.44M-2.94M1.15M2.58M
Change in Inventory
-546.89K-341.36K72.56K-314.2K-409.82K-2.18M764.33K675.67K303.24K399.77K
Change in Payables
-227.23K6.34K1.89M8.93M-893.96K1.25M978.06K4.92M3.24M11.08M
Cash from Investing
63.38K141.44K-100K-798.14K-3.4M-13.91M-8.73M-11.54M6.91M7.72M
Capital Expenditures
0-100K0-398.14K-247.37K-366.63K-203.81K-1.49M0-1.02M
CapEx % of Revenue
-1.2%-1.07%0.27%0.31%0.13%0.7%0.96%0.46%
Acquisitions
63.38K241.44K-100K-400K0-1.01M0000
Investments
----------
Other Investing
0290K-100K0-3.15M-12.53M-8.53M-10.05M6.91M8.74M
Cash from Financing
776.03K802.79K775.12K21M68.64M-528.2K29.1M-4.12M-13.41M-13.29M
Debt Issued (Net)
116.06K642.44K798.28K93.19K-530.82K2.74M16.67M-327.6K-18.72M-18.72M
Equity Issued (Net)
596.6K0350K20.13M69.33M016.2M09.19M9.27M
Dividends Paid
000-1.29M-871.48K-3.11M-3.11M-3.11M-3.11M-3.11M
Share Repurchases
-76.65K000000000
Other Financing
63.38K160.35K-373.15K2.07M707.36K-159.2K-667.63K-684.83K-773.66K-737.66K
Net Change in Cash
-41.18K▲ 0%
38.71K▲ 194.0%
926.53K▲ 2293.3%
8.07M▲ 771.3%
32.15M▲ 298.3%
-37.37M▼ 216.2%
29.19M▲ 178.1%
1.86M▼ 93.6%
1.78M▼ 4.1%
84.73K▲ 0%
Free Cash Flow
-817.22K▲ 0%
-1.01M▼ 23.0%
251.41K▲ 125.0%
-12.53M▼ 5083.8%
-36.49M▼ 191.2%
-35.83M▲ 1.8%
86.95K▲ 100.2%
5.98M▲ 6774.1%
6.41M▲ 7.2%
14.83M▲ 0%
FCF Margin %
-16.17%-12.08%2.02%-33.6%-39.29%-30.1%0.06%2.81%3.3%6.76%
FCF Growth %
-100.34%-23.04%125%-5083.83%-191.21%1.81%100.24%6774.08%7.24%368.41%
FCF per Share
-0.09-0.110.03-0.88-1.35-1.160.000.150.140.31
FCF Conversion (FCF/Net Income)
0.68x0.73x-0.08x0.21x0.54x0.50x-0.43x-0.93x-1.17x-0.87x
Interest Paid
0000435.05K189K0000
Taxes Paid
0000000000

LFMD Key Ratios

LifeMD, Inc. (LFMD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201720182019202020212022202320242025TTM
Return on Equity (ROE)
-923.7%-172.03%---487.23%-491.92%-370.02%-2483.15%-74.37%-162.38%
Return on Invested Capital (ROIC)
-514.86%-200.79%-------80.21%
Gross Margin
70.65%76.35%79.75%76.24%80.62%84.32%87.61%88.67%79.75%86.65%
Net Margin
-23.86%-14.91%-25.16%-157.26%-65.57%-38.25%-13.5%-8.89%-3.66%-7.76%
Debt / Equity
0.27x0.30x--0.07x-3.40x-0.27x0.41x
Interest Coverage
-12.72x-5.80x-3.80x-34.67x-17.98x-31.10x-5.58x-7.40x-5.64x-6.48x
FCF Conversion
0.68x0.73x-0.08x0.21x0.54x0.50x-0.43x-0.93x-1.17x-0.87x
Revenue Growth
-3.51%64.68%49.79%199.1%149.04%28.16%28.15%39.27%-8.66%-6.18%
Related:LFMD Dividend History·LFMD Revenue History·LFMD Price History·LFMD P/E History·LFMD Financial Ratios·LFMD Institutional Holders

LFMD SEC Filings & Documents

LifeMD, Inc. (LFMD) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 6, 2026·SEC

Material company update

Mar 18, 2026·SEC

Material company update

Mar 9, 2026·SEC

10-K Annual Reports

4
FY 2026

Mar 10, 2026·SEC

FY 2025

Mar 11, 2025·SEC

FY 2024

Mar 11, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 6, 2026·SEC

FY 2025

Nov 17, 2025·SEC

FY 2025

Aug 5, 2025·SEC

LFMD Frequently Asked Questions

LifeMD, Inc. (LFMD) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

LifeMD, Inc. (LFMD) reported $219.4M in revenue for fiscal year 2025. This represents a 29399% increase from $0.7M in 2011.

LifeMD, Inc. (LFMD) saw revenue decline by 8.7% over the past year.

LifeMD, Inc. (LFMD) reported a net loss of $17.0M for fiscal year 2025.

Dividend & Returns

Yes, LifeMD, Inc. (LFMD) pays a dividend with a yield of 1.45%. This makes it attractive for income-focused investors.

LifeMD, Inc. (LFMD) has a return on equity (ROE) of -74.4%. Negative ROE indicates the company is unprofitable.

LifeMD, Inc. (LFMD) generated $14.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in LFMD back in 2011?

Total return calculator · dividends reinvested · 15+ years of data

See returns →

How much would $100/month in LFMD be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →